Quick Answer
Regencell Bioscience Holdings Ltd reported Diluted EPS of $0.72 per share (loss) for fiscal year 2025.
Regencell Bioscience Holdings Ltd Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.72 | +17.2% |
| 2024 | -$0.87 | +26.9% |
| 2023 | -$1.19 | -105.2% |
| 2022 | -$0.58 | -346.2% |
| 2021 | -$0.13 | -62.5% |
| 2020 | -$0.08 | — |
- Regencell Bioscience Holdings Ltd showed an increase of +17.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Regencell Bioscience Holdings Ltd’s diluted eps has declined by 800.0% (from $0.08 per share (loss) to $0.72 per share (loss)).
- The most recent figure is from Regencell Bioscience Holdings Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on October 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: